United Kingdom Researchers study Tesamorelin because it is a synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates growth hormone release
in preclinical and in-vitro systems it has been studied as a GHRH-receptor agonist on anterior pituitary cells, where it has been observed to stimulate the synthesis and pulsatile release of endogenous growth hormone
Test animals with GHD had about 20% lower lean body weight than the norm and could not reach normal body length or weight
Common side effects by peptide type Growth hormone peptides: Water retention (temporary) Lethargy initially (adapts within weeks) Carpal tunnel symptoms (rare, high doses) Insulin resistance (monitor with long-term use) IGF-1 LR3: Hypoglycemia (keep fast carbs on hand) Jaw/facial bone growth (with chronic use) Organ enlargement (long-term misuse) Healing peptides: Minimal side effects Occasionally: fatigue, headache (rare) Monitoring and bloodwork Baseline testing before starting: IGF-1 levels Thyroid panel (T3, T4, TSH) Fasting glucose and insulin Lipid panel Liver and kidney function Follow-up testing: Every 3-6 months during protocol Monitor IGF-1 (ensure not excessively elevated) Check glucose metabolism Liver/kidney function Contraindications Avoid peptides if: Active cancer (GH/IGF-1 can promote tumor growth) Diabetic without physician oversight Significant organ disease Use caution if: Family history of cancer Pre-diabetic Taking medications that affect blood sugar See our peptide safety and risks guide for comprehensive safety information
Common analytical methods include HPLC, mass spectrometry, molecular weight analysis, and analytical assay verification
The broader Spartan research library covers the GH/IGF axis in more detail across multiple compound entries
